Quantification of the heterogeneity of prognostic cellular biomarkers in ewing sarcoma using automated image and random survival forest analysis

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Bühnemann, Claudia ^a   Li, Simon ^a   Yu, Haiyue ^a   White, Harriet Branford ^a   Schäfer, Karl L ^b   Llombart Bosch, Antonio ^c   Machado, Isidro ^c   Picci, Piero ^d   Hogendoorn, Pancras C W ^e   Athanasou, Nicholas A ^f   Noble, J Alison ^a   Hassan, A Bassim ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c UNIVERSITY OF VALENCIA   (Spain)

^d RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^f UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4',6 DIAMIDINO 2 PHENYLINDOLE; CD99 ANTIGEN; EARLY GROWTH RESPONSE FACTOR 1; KI 67 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR FKHRL1; TUMOR MARKER; CD99 PROTEIN, HUMAN; CELL ADHESION MOLECULE; LEUKOCYTE ANTIGEN;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CELL DENSITY; CELL HETEROGENEITY; CELL NUCLEUS; CELL SUBPOPULATION; CLASSIFIER; CONTROLLED STUDY; CYTOARCHITECTURE; CYTOPLASM; DECISION TREE; EWING SARCOMA; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMAGE ANALYSIS; IMAGE PROCESSING; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROTEIN LOCALIZATION; RANDOM FOREST; RANDOM SURVIVAL FOREST ANALYSIS; SURVIVAL PREDICTION; VALIDATION PROCESS; ALGORITHM; ARTIFICIAL INTELLIGENCE; BONE TUMOR; METABOLISM; PATHOLOGY; PROGNOSIS; TUMOR CELL LINE;

ALGORITHMS; ANTIGENS, CD; ARTIFICIAL INTELLIGENCE; BONE NEOPLASMS; CELL ADHESION MOLECULES; CELL LINE, TUMOR; CELL NUCLEUS; CYTOPLASM; HUMANS; PROGNOSIS; SARCOMA, EWING; TUMOR MARKERS, BIOLOGICAL;

EID: 84907190330     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0107105     Document Type: Article

References (69)

1. Hanahan D,Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144: 646-674.
2. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, et al. (2013) Signatures of mutational processes in human cancer. Nature 500: 415-421.
3. Tyers M, Mann M (2003) From genomics to proteomics. Nature 422: 193-197.
4. Meacham CE, Morrison SJ (2013) Tumour heterogeneity and cancer cell plasticity. Nature 501: 328-337.
5. Murtaza M, Dawson SJ, Tsui DW, Gale D, Forshew T, et al. (2013) Noninvasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 497: 108-112.
6. Hou Y, Song L, Zhu P, Zhang B, Tao Y, et al. (2012) Single-cell exome sequencing and monoclonal evolution of a JAK2-negative myeloproliferative neoplasm. Cell 148: 873-885.
7. Murchison EP, Schulz-Trieglaff OB, Ning Z, Alexandrov LB, Bauer MJ, et al. (2012) Genome sequencing and analysis of the Tasmanian devil and its transmissible cancer. Cell 148: 780-791.
8. Navin N, Kendall J, Troge J, Andrews P, Rodgers L, et al. (2011) Tumour evolution inferred by single-cell sequencing. Nature 472: 90-94.
9. Yachida S, Jones S, Bozic I, Antal T, Leary R, et al. (2010) Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467: 1114-1117.
10. De Palma M, Hanahan D (2012) The biology of personalized cancer medicine: facing individual complexities underlying hallmark capabilities. Mol Oncol 6: 111-127.
11. Yap TA, Gerlinger M, Futreal PA, Pusztai L, Swanton C (2012) Intratumor heterogeneity: seeing the wood for the trees. Sci Transl Med 4: 127ps110.
12. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, et al. (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366: 883-892.
13. Xu X, Hou Y, Yin X, Bao L, Tang A, et al. (2012) Single-cell exome sequencing reveals single-nucleotide mutation characteristics of a kidney tumor. Cell 148: 886-895.
14. Ginty F, Adak S, Can A, Gerdes M, Larsen M, et al. (2008) The relative distribution of membranous and cytoplasmic met is a prognostic indicator in stage I and II colon cancer. Clin Cancer Res 14: 3814-3822.
15. Casadonte R, Caprioli RM (2011) Proteomic analysis of formalin-fixed paraffinembedded tissue by MALDI imaging mass spectrometry. Nat Protoc 6: 1695-1709.
16. Jones EA, van Remoortere A, van Zeijl RJ, Hogendoorn PC, Bovee JV, et al. (2011) Multiple statistical analysis techniques corroborate intratumor heterogeneity in imaging mass spectrometry datasets of myxofibrosarcoma. PLoS One 6: e24913.
17. Rahman SM, Gonzalez AL, Li M, Seeley EH, Zimmerman LJ, et al. (2011) Lung cancer diagnosis from proteomic analysis of preinvasive lesions. Cancer Res 71: 3009-3017.
18. Seeley EH, Caprioli RM (2011) MALDI imaging mass spectrometry of human tissue: method challenges and clinical perspectives. Trends Biotechnol 29: 136-143.
19. Camp RL, Chung GG, Rimm DL (2002) Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med 8: 1323-1327.
20. Friedenberger M, Bode M, Krusche A, Schubert W (2007) Fluorescence detection of protein clusters in individual cells and tissue sections by using toponome imaging system: sample preparation and measuring procedures. Nat Protoc 2: 2285-2294.
21. Schubert W, Bonnekoh B, Pommer AJ, Philipsen L, Bockelmann R, et al. (2006) Analyzing proteome topology and function by automated multidimensional fluorescence microscopy. Nat Biotechnol 24: 1270-1278.
22. Budczies J, Klauschen F, Sinn BV, Gyorffy B, Schmitt WD, et al. (2012) Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization. PLoS One 7: e51862.
23. Klauschen F, Ishii M, Qi H, Bajenoff M, Egen JG, et al. (2009) Quantifying cellular interaction dynamics in 3D fluorescence microscopy data. Nat Protoc 4: 1305-1311.
24. Klauschen F, Qi H, Egen JG, Germain RN, Meier-Schellersheim M (2009) Computational reconstruction of cell and tissue surfaces for modeling and data analysis. Nat Protoc 4: 1006-1012.
25. Neumeister VM, Anagnostou V, Siddiqui S, England AM, Zarrella ER, et al. (2012) Quantitative assessment of effect of preanalytic cold ischemic time on protein expression in breast cancer tissues. J Natl Cancer Inst 104: 1815-1824.
26. Kayser K (2012) Introduction of virtual microscopy in routine surgical pathology-a hypothesis and personal view from Europe. Diagn Pathol 7: 48.
27. Sharma H, Alekseychuk A, Leskovsky P, Hellwich O, Anand RS, et al. (2012) Determining similarity in histological images using graph-theoretic description and matching methods for content-based image retrieval in medical diagnostics. Diagn Pathol 7: 134.
28. Gatta G, van der Zwan JM, Casali PG, Siesling S, Dei Tos AP, et al. (2011) Rare cancers are not so rare: the rare cancer burden in Europe. Eur J Cancer 47: 2493-2511.
29. Bernstein M, Kovar H, Paulussen M, Randall RL, Schuck A, et al. (2006) Ewing's sarcoma family of tumors: current management. Oncologist 11: 503-519.
30. Le Deley MC, Paulussen M, Lewis I, Brennan B, Ranft A, et al. (2014) Cyclophosphamide Compared With Ifosfamide in Consolidation Treatment of Standard-Risk Ewing Sarcoma: Results of the Randomized Noninferiority Euro- EWING99-R1 Trial. J Clin Oncol.
31. de Alava E, Antonescu CR, Panizo A, Leung D, Meyers PA, et al. (2000) Prognostic impact of P53 status in Ewing sarcoma. Cancer 89: 783-792.
32. Mackintosh C, Ordonez JL, Garcia-Dominguez DJ, Sevillano V, Llombart- Bosch A, et al. (2012) 1q gain and CDT2 overexpression underlie an aggressive and highly proliferative form of Ewing sarcoma. Oncogene 31: 1287-1298.
33. van Maldegem AM, Hogendoorn PC, Hassan AB (2012) The clinical use of biomarkers as prognostic factors in Ewing sarcoma. Clin Sarcoma Res 2: 7.
34. Lopez-Guerrero JA, Machado I, Scotlandi K, Noguera R, Pellin A, et al. (2011) Clinicopathological significance of cell cycle regulation markers in a large series of genetically confirmed Ewing's sarcoma family of tumors. Int J Cancer 128: 1139-1150.
35. Juergens H, Daw NC, Geoerger B, Ferrari S, Villarroel M, et al. (2011) Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma. J Clin Oncol 29: 4534-4540.
36. Pappo AS, Patel SR, Crowley J, Reinke DK, Kuenkele KP, et al. (2011) R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study. J Clin Oncol 29: 4541-4547.
37. Ottaviano L, Schaefer KL, Gajewski M, Huckenbeck W, Baldus S, et al. (2010) Molecular characterization of commonly used cell lines for bone tumor research: a trans-European EuroBoNet effort. Genes Chromosomes Cancer 49: 40-51.
38. Otsu N (1979) A threshold selection method from gray-level histograms. IEEE Trans Sys, Man, Cyber 9: 62-66.
39. Lankton S, Tannenbaum A (2008) Localizing region-based active contours. IEEE Trans Image Process 17: 2029-2039.
40. Jones TR, Carpenter A, Golland P (2005) Voronoi-based segmentation of cells on image manifolds. Computer Vision for Biomedical Image Applications, Proceedings 3765: 535-543.
41. Bray MA, Fraser AN, Hasaka TP, Carpenter AE (2012) Workflow and Metrics for Image Quality Control in Large-Scale High-Content Screens. Journal of Biomolecular Screening 17: 266-274.
42. Haralick RM (1979) Statistical and Structural Approaches to Texture. Proceedings of the Ieee 67: 786-804.
43. Harrell FE, Jr., Califf RM, Pryor DB, Lee KL, Rosati RA (1982) Evaluating the yield of medical tests. JAMA 247: 2543-2546.
44. Holzer TR, Fulford AD, Arkins AM, Grondin JM, Mundy CW, et al. (2011) Ischemic time impacts biological integrity of phospho-proteins in PI3K/Akt, Erk/MAPK, and p38 MAPK signaling networks. Anticancer Res 31: 2073-2081.
45. Beck AH, Sangoi AR, Leung S, Marinelli RJ, Nielsen TO, et al. (2011) Systematic analysis of breast cancer morphology uncovers stromal features associated with survival. Sci Transl Med 3: 108ra113.
46. Breiman L (2001) Random forests. Machine Learning 45: 5-32.
47. Seligson DB, Horvath S, Shi T, Yu H, Tze S, et al. (2005) Global histone modification patterns predict risk of prostate cancer recurrence. Nature 435: 1262-1266.
48. Ishwaran H, Kogalur UB (2010) Consistency of Random Survival Forests. Stat Probab Lett 80: 1056-1064.
49. Ishwaran H, Kogalur UB, Blackstone EH, Lauer MS (2008) Random Survival Forests. Annals of Applied Statistics 2: 841-860.
50. Sompallae R, Hofmann O, Maher CA, Gedye C, Behren A, et al. (2013) A comprehensive promoter landscape identifies a novel promoter for CD133 in restricted tissues, cancers, and stem cells. Front Genet 4: 209.
51. Jiang X, Gwye Y, Russell D, Cao C, Douglas D, et al. (2010) CD133 expression in chemo-resistant Ewing sarcoma cells. BMC Cancer 10: 116.
52. Suva ML, Riggi N, Stehle JC, Baumer K, Tercier S, et al. (2009) Identification of cancer stem cells in Ewing's sarcoma. Cancer Res 69: 1776-1781.
53. Dolled-Filhart M, Gustavson M, Camp RL, Rimm DL, Tonkinson JL, et al. (2010) Automated analysis of tissue microarrays. Methods Mol Biol 664: 151-162.
54. Chen X, Wang L, Ishwaran H (2010) An Integrative Pathway-based Clinicalgenomic Model for Cancer Survival Prediction. Stat Probab Lett 80: 1313-1319.
55. Berger AJ, Camp RL, Divito KA, Kluger HM, Halaban R, et al. (2004) Automated quantitative analysis of HDM2 expression in malignant melanoma shows association with early-stage disease and improved outcome. Cancer Res 64: 8767-8772.
56. Bunyak F, Hafiane A, Palaniappan K (2011) Histopathology tissue segmentation by combining fuzzy clustering with multiphase vector level sets. Adv Exp Med Biol 696: 413-424.
57. Jones TR, Carpenter AE, Lamprecht MR, Moffat J, Silver SJ, et al. (2009) Scoring diverse cellular morphologies in image-based screens with iterative feedback and machine learning. Proc Natl Acad Sci U S A 106: 1826-1831.
58. Rittscher J (2010) Characterization of biological processes through automated image analysis. Annu Rev Biomed Eng 12: 315-344.
59. Shi T, Seligson D, Belldegrun AS, Palotie A, Horvath S (2005) Tumor classification by tissue microarray profiling: random forest clustering applied to renal cell carcinoma. Mod Pathol 18: 547-557.
60. Bai Y, Tolles J, Cheng H, Siddiqui S, Gopinath A, et al. (2011) Quantitative assessment shows loss of antigenic epitopes as a function of pre-analytic variables. Lab Invest 91: 1253-1261.
61. Portier BP, Wang Z, Downs-Kelly E, Rowe J J, Patil D, et al. (2013) Delay to formalin fixation 'cold ischemia time': effect on ERBB2 detection by in-situ hybridization and immunohistochemistry. Mod Pathol 26: 1-9.
62. Bonnas C, Specht K, Spleiss O, Froehner S, Dietmann G, et al. (2012) Effects of cold ischemia and inflammatory tumor microenvironment on detection of PI3K/AKT and MAPK pathway activation patterns in clinical cancer samples. Int J Cancer 131: 1621-1632.
63. DiVito KA, Charette LA, Rimm DL, Camp RL (2004) Long-term preservation of antigenicity on tissue microarrays. Lab Invest 84: 1071-1078.
64. Tirode F, Laud-Duval K, Prieur A, Delorme B, Charbord P, et al. (2007) Mesenchymal stem cell features of Ewing tumors. Cancer Cell 11: 421-429.
65. De Vito C, Riggi N, Cornaz S, Suva ML, Baumer K, et al. (2012) A TARBP2- dependent miRNA expression profile underlies cancer stem cell properties and provides candidate therapeutic reagents in Ewing sarcoma. Cancer Cell 21: 807-821.
66. Riggi N, Suva ML, De Vito C, Provero P, Stehle JC, et al. (2010) EWS-FLI-1 modulates miRNA145 and SOX2 expression to initiate mesenchymal stem cell reprogramming toward Ewing sarcoma cancer stem cells. Genes Dev 24: 916-932.
67. Guo Y, Graber A, McBurney RN, Balasubramanian R (2010) Sample size and statistical power considerations in high-dimensionality data settings: a comparative study of classification algorithms. BMC Bioinformatics 11: 447.
68. Kong J, Cooper LA, Wang F, Gao J, Teodoro G, et al. (2013) Machine-based morphologic analysis of glioblastoma using whole-slide pathology images uncovers clinically relevant molecular correlates. PLoS One 8: e81049.
69. Yuan Y, Failmezger H, Rueda OM, Ali HR, Graf S, et al. (2012) Quantitative image analysis of cellular heterogeneity in breast tumors complements genomic profiling. Sci Transl Med 4: 157ra143.